{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:18:09Z","timestamp":1788848289354,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T00:00:00Z","timestamp":1498694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Stem Cell Cancer and Regenerative Medicine Research Inc."},{"name":"Life Extension Foundation"}],"content-domain":{"domain":["heliyon.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.heliyon.2017.e00438","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T09:54:33Z","timestamp":1509443673000},"page":"e00438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Young donor white blood cell immunotherapy induces extensive tumor necrosis in advanced-stage solid tumors"],"prefix":"10.1016","volume":"3","author":[{"given":"Dipnarine","family":"Maharaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro G.","family":"Vianna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Rayborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline V.","family":"Gouvea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2017.e00438_bib0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med."},{"issue":"9","key":"10.1016\/j.heliyon.2017.e00438_bib0010","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.heliyon.2017.e00438_bib0015","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2017.e00438_bib0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2867-11-26","article-title":"Novel innate cancer killing activity in humans","volume":"11","author":"Blanks","year":"2011","journal-title":"Cancer Cell Int."},{"issue":"20","key":"10.1016\/j.heliyon.2017.e00438_bib0025","doi-asserted-by":"crossref","first-page":"7753","DOI":"10.1073\/pnas.0602382103","article-title":"Transferable anticancer innate immunity in spontaneous regression\/complete resistance mice","volume":"103","author":"Hicks","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.heliyon.2017.e00438_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005339","article-title":"Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction","volume":"3","author":"Stanworth","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.heliyon.2017.e00438_bib0035","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1046\/j.1365-2141.1999.01619.x","article-title":"Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients","volume":"106","author":"Peters","year":"1999","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.heliyon.2017.e00438_bib0040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.leu.2402007","article-title":"Clinical efficacy of granulocyte transfusion therapy in patients with neutropenia-related infections","volume":"15","author":"Lee","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2017.e00438_bib0045","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/1471-2407-9-328","article-title":"Impact of sex, MHC, and age of recipients on the therapeutic effect of transferred leukocytes from cancer-resistant SR\/CR mice","volume":"9","author":"Stehle","year":"2009","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.heliyon.2017.e00438_bib0050","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.1031601100","article-title":"Spontaneous regression of advanced cancer: identification of a unique genetically determined, age-dependent trait in mice","volume":"100","author":"Cui","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.heliyon.2017.e00438_bib0055","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00262-003-0488-2","article-title":"The effect of aging on cellular immunity against cancer in SR\/CR mice","volume":"53","author":"Cui","year":"2004","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.heliyon.2017.e00438_bib0060","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1471-2407-10-121","article-title":"Cancer resistance of SR\/CR mice in the genetic knockout backgrounds of leukocyte effector mechanisms: determinations for functional requirements","volume":"10","author":"Sanders","year":"2010","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.heliyon.2017.e00438_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065334","article-title":"Prevention of Transfusion-Associated Graft-versus-Host Disease by Irradiation: Technical Aspect of a New Ferrous Sulphate Dosimetric System","volume":"8","author":"Del Lama","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.heliyon.2017.e00438_bib0070","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/leu.2012.301","article-title":"A prospective, randomized, double-blind study, comparing unirradiated to irradiated white blood cell transfusions in acute leukemia patients","volume":"27","author":"Freireich","year":"2013","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.heliyon.2017.e00438_bib0075","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.it.2010.05.006","article-title":"Neutrophil kinetics in health and disease","volume":"31","author":"Summers","year":"2010","journal-title":"Trends Immunol."},{"issue":"12","key":"10.1016\/j.heliyon.2017.e00438_bib0080","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.3324\/haematol.2009.013680","article-title":"Granulocyte transfusion therapy: randomization after all?","volume":"94","author":"Drewniak","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.heliyon.2017.e00438_bib0085","first-page":"1","article-title":"Hematological and iron-related analytes?reference data for persons aged 1 year and over: United States, 1988-94","volume":"247","author":"Hollowell","year":"2005","journal-title":"Vital Health Stat."},{"issue":"4","key":"10.1016\/j.heliyon.2017.e00438_bib0090","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1084\/jem.165.4.941","article-title":"Recombinant human granulocyte colony-stimulating factor: Effects on hematopoiesis in normal and cyclophosphamide-treated primates","volume":"165","author":"Welte","year":"1987","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2017.e00438_bib0095","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin. Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2017.e00438_bib0100","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.heliyon.2017.e00438_bib0105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(97)00398-7","article-title":"Transient abnormalities in serum bilirubin and lactate dehydrogenase levels following red blood cell transfusions in adults","volume":"104","author":"Wiesen","year":"1998","journal-title":"Am. J. Med."},{"issue":"7","key":"10.1016\/j.heliyon.2017.e00438_bib0110","first-page":"439","article-title":"Diagnostic and prognostic value of very high serum lactate dehydrogenase in admitted medical patients","volume":"16","author":"Erez","year":"2014","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.heliyon.2017.e00438_bib0115","first-page":"11","article-title":"Effector mechanisms of the anti-cancer immune responses of macrophages in SR\/CR mice","volume":"6","author":"Hicks","year":"2006","journal-title":"Cancer Immun."},{"issue":"1","key":"10.1016\/j.heliyon.2017.e00438_bib0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1471-2407-10-179","article-title":"The spectrum of resistance in SR\/CR mice: the critical role of chemoattraction in the cancer\/leukocyte interaction","volume":"10","author":"Riedlinger","year":"2010","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.heliyon.2017.e00438_bib0125","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.heliyon.2017.e00438_bib0130","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"16","key":"10.1016\/j.heliyon.2017.e00438_bib0135","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2017.e00438_bib0140","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/imr.12154","article-title":"Transplantation tolerance: from theory to clinic","volume":"258","author":"Fuchs","year":"2014","journal-title":"Immunol. Rev. Mar"},{"issue":"7","key":"10.1016\/j.heliyon.2017.e00438_bib0145","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"3","key":"10.1016\/j.heliyon.2017.e00438_bib0150","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2141.2004.05328.x","article-title":"Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation","volume":"128","author":"Dey","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.heliyon.2017.e00438_bib0155","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood-2010-06-288506","article-title":"Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients","volume":"117","author":"Guo","year":"2011","journal-title":"Blood"},{"issue":"33","key":"10.1016\/j.heliyon.2017.e00438_bib0160","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1200\/JCO.2012.42.0281","article-title":"HLA-Mismatched Stem-Cell Microtransplantation As Postremission Therapy for Acute Myeloid Leukemia: Long-Term Follow-Up","volume":"30","author":"Guo","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.heliyon.2017.e00438_bib0165","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1470-2045(04)01505-0","article-title":"Halo naevus: a visible case of immunosurveillance in humans?","volume":"5","author":"Cui","year":"2004","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2017.e00438_bib0170","series-title":"Considering Cost: What's an Immunotherapy Worth?","author":"Incollingo","year":"2015"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844017316936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844017316936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T07:27:15Z","timestamp":1535268435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844017316936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S2405844017316936"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2017.e00438","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Young donor white blood cell immunotherapy induces extensive tumor necrosis in advanced-stage solid tumors","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2017.e00438","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 South Florida Bone Marrow Stem Cell Transplant Institute.LLC. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e00438"}}